YB new stock pitches (Wed, Jul 8)

XPeng ($XPEV) is valued by the market purely as a struggling EV maker with deliveries rolling over in 2026, while ignoring its second business: IRON, a humanoid robot heading for mass production this year, which the pitch frames as free optionality embedded in the current price. The strongest signal is founder He Xiaopeng personally taking command of the robotics unit on June 10, 2026, comparing the moment to the eve of XPENG's first car launch eight years ago; the team is now past 1,000 people, held a 'mass-production sprint' rally in late May pulling staff from auto, powertrain, manufacturing, testing and AI, and the company even dropped 'Motors' from its Chinese name. IRON is full-stack and in-house (3x Turing chips, VLA 2.0 brain, motors, joints, 22-DOF hands, solid-state battery, and OS), claimed to be the only Chinese robotics firm with a fully self-developed full stack, and it leverages the same supply chain and lines that ship 300k+ EVs a year as a launchpad, mirroring Tesla's Optimus bet. The catalyst calendar is concrete: Q1 2026 Guangzhou 110,000 m² factory groundbreaking (done), Q2 'full capability integration,' ~November AI Day (key catalyst for the production-grade Gen-8 reveal and pricing), end-2026 mass production start, and Q1 2027 first units in XPENG showrooms, with an ambition of 1 million IRON units/year by 2030 and robot sales eventually surpassing car sales within a decade (framed as vision, not guidance). AI Day (~November) is the biggest near-term event and where the robot optionality gets tested; the chart has been down-only, but the author believes robotics momentum will draw more eyes to the name.

Read the full article here. Read time: 2 min

Vera Therapeutics ($VERA), an IgA nephropathy (IgAN) play trading at $41 (~$3B market cap, ~$2.4B EV) with a $90 price target and 100%+ upside potential, is a long ahead of its atacicept accelerated approval PDUFA on Monday or Tuesday this week. Friday's selloff was driven by an Otsuka competitive headline that the author views as overdone, as the market is trading competitive optics while ignoring the expanding TAM: KDIGO 2025 guidelines lowered treatment thresholds (biopsy recommended at possible IgAN with proteinuria >0.5 g/day or reduced eGFR, treatment target dropped to <0.5 g/day, ideally <0.3), pulling a materially larger population into active treatment and pushing the estimated TAM to $20–30B (vs. the anchored ~100k US patients, plus ~50k across just 10 European countries and high China/Asia burden). Revenue math shows ~2,500 treated patients yields ~$1B; at ~$300k net (23% GTN) and 15k patients that's $4.5B, or at ~$250k net (36% GTN) and 20k patients, $5B (Otsuka added ~880 patients in Q1 alone). A KOL survey shows docs expect ~75% of IgAN patients on new agents, ERAs and B-cell agents each reaching 35–40% within 5 years (B-cell penetration ~17% by 6 months, ~30% within a year), with intra-class share of sibeprenlimab ~19%, atacicept ~12%, povetacicept ~12%; nephrologists view atacicept, povetacicept, and sibeprenlimab as comparable on efficacy, with atacicept slightly weaker only on dosing cadence (weekly)—a gap monthly dosing data would close—while class-wide payer friction (prior auths, step-throughs) is the real gating factor rather than a $VERA-specific issue, and ~half of docs would consider combos (B-cell + ERA), validating the stacking-to-UPCR<0.3 thesis. Atacicept is a native human TACI-Fc with no ADAs, placebo-comparable safety, a 42% placebo-adjusted UPCR reduction at week 36 (published in NEJM), ~93% OLE compliance, and an at-home autoinjector; cross-trial comps to Otsuka's ~51% proteinuria are not clinically or statistically different. With sell-side consensus around ~$2.1B WW peak and ~$2B US peak alone against a ~$2.4B EV, investors pay EV for the conservative case and get KDIGO expansion, ex-US, combos, and pipeline optionality (Sjögren's, FSGS), strengthened IP, and M&A potential ($AMGN, $PFE, $LLY) for free, alongside a credible path to monthly dosing. Key downside risks: Otsuka dominating monthly dosing, a stronger Otsuka launch/eGFR data, atacicept getting a standard rather than expedited approval, improved $VRTX execution, or a competitor printing a 6-handle proteinuria number. The author remains long, calling it a no-brainer given the market size and physician preferences.

Read the full article here. Read time: 3 min

Bénéteau S.A. (BEN.PA) is a French recreational boat manufacturer operating through Groupe Beneteau, designing and selling sailing yachts, motorboats, monohulls, and catamarans across multiple brands via a global production and dealer network, while also expanding into boating-related services such as charter operations, marina services, digital solutions, boat clubs, and financing to create recurring revenue. Trading at a €524.8M market cap and €600.3M EV, the company has a 22.2% ROIC and a 0.77 P/TB. Its balance sheet is unusually strong, with current assets exceeding total liabilities by roughly €300M, implying investors are paying only about €200M for fixed assets, intellectual property, brands, and a positively inflecting order book (order intake up 24% YoY, order book up ~10%). Between 2017 and 2024, EBIT fell below €80M only once (during COVID in 2020), so using €80M as normalized operating earnings implies an EV/EBIT of ~2.5x—and substantially lower after adjusting for excess working capital—suggesting the shares trade at a deep discount to intrinsic value.

Read the full article here. Read time: 1 min